CTLA4 and melanoma: This story begins with the success of translating the basic immunologic observation that CTLA-4 is a negative regulator of T cells into the preclinical observation that blockade of CTLA-4 can have potent anti-tumor activity in mouse models, and then into the subsequent clinical trials that tested this concept in a population of patients with advanced melanoma (1–7).